Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
VeracyteVCYT -0.49%75 EV-to-EBIT is 47.67 as of Jul. 16, 2026. GuruFocus rates VCYT with a GF Score™ of 75/100 and a GF Value™ of $38.31 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 104 Medical Diagnostics & Research companies, Veracyte ranks worse than 85.58% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Veracyte's Enterprise Value for the quarter that ended in Mar. 2026 was $2,170.4 Mil.
Veracyte's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $90.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Veracyte EV-to-EBIT Related Terms
Veracyte EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Veracyte's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Veracyte's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Veracyte EV-to-EBIT vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Veracyte's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Veracyte's EV-to-EBIT falls into.
Veracyte's current Enterprise Value is $4,325.6 Mil.
Veracyte's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $90.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Veracyte (VCYT) has a EV-to-EBIT of 47.67 as of Jul. 16, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Veracyte and its competitors. According to the industry distribution chart, Veracyte ranks #89 out of 104 companies in the Medical Diagnostics & Research industry, placing it in the top 85.6%.
Is Veracyte's EV-to-EBIT too high?
Veracyte's current EV-to-EBIT is 47.67. The Medical Diagnostics & Research industry median EV-to-EBIT is 23.23. Veracyte's value of 47.67 is 105.3% above this industry median. Based on the distribution chart, Veracyte ranks #89 out of 104 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Veracyte has a GF Score™ of 75/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Veracyte's EV-to-EBIT compare to RDNT and SHC?
According to the Medical Diagnostics & Research industry distribution chart, Veracyte ranks #89 out of 104 companies for EV-to-EBIT. This places Veracyte in the lower half of its industry. The industry median EV-to-EBIT is 23.23. Veracyte's value of 47.67 is 105.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Diagnostics & Research company?
The median EV-to-EBIT among Medical Diagnostics & Research companies is 23.23, based on 104 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Veracyte's current EV-to-EBIT of 47.67 is 105.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Veracyte and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-EBIT is 23.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Veracyte's current EV-to-EBIT is 47.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veracyte stock overvalued right now?
Based on GuruFocus' analysis, Veracyte (VCYT) is currently considered Significantly Overvalued. The stock's GF Value™ is $38.31, compared to a current price of $59.23 — trading 54.6% above its estimated fair value. The current EV-to-EBIT is 47.67 and 105.3% above the Medical Diagnostics & Research industry median of 23.23. Veracyte's overall GF Score™ is 75/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Veracyte (VCYT), the current EV-to-EBIT is 47.67 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Veracyte (VCYT) Overvalued in 2026?
Based on GuruFocus' analysis, Veracyte stock appears to be overvalued.
The current stock price of $59.23 is trading 54.6% above its estimated GF Value™ of $38.31.
GuruFocus considers Veracyte to be Significantly Overvalued.
Key valuation signals for VCYT:
EV-to-EBIT: 47.67
GF Value™: $38.31 vs. price of $59.23 (54.6% above fair value)
Industry Position: 105.3% above the Medical Diagnostics & Research median (#89 of 104)
No single metric tells the full story. See the VCYT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).
75GF Score
Get the complete analysis for VCYT
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VCYT has been successfully added to your 
